Licia Rivoltini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3549246/publications.pdf

Version: 2024-02-01

213 papers	19,496 citations	13099 68 h-index	11607 135 g-index
224 all docs	224 docs citations	224 times ranked	22745 citing authors

#	Article	IF	Citations
1	Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3515-3519.	7.1	987
2	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	2.5	806
3	Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.. Journal of Experimental Medicine, 1994, 180, 347-352.	8.5	771
4	Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles. Journal of Experimental Medicine, 2002, 195, 1303-1316.	8.5	660
5	Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factorâ€“Based Antitumor Vaccine. Journal of Clinical Oncology, 2007, 25, 2546-2553.	1.6	606
6	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.9	470
7	Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-Î²â€“Mediated Suppressive Activity on T Lymphocytes. Cancer Research, 2006, 66, 9290-9298.	0.9	455
8	Human Colorectal Cancer Cells Induce T-Cell Death Through Release of Proapoptotic Microvesicles: Role in Immune Escape. Gastroenterology, 2005, 128, 1796-1804.	1.3	453
9	Tumour-released exosomes and their implications in cancer immunity. Cell Death and Differentiation, 2008, 15, 80-88.	11.2	452
10	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 107-120.	7.3	433
11	Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars in Cancer Biology, 2017, 43, 74-89.	9.6	414
12	Potential role of HER2â€overexpressing exosomes in countering trastuzumabâ€based therapy. Journal of Cellular Physiology, 2012, 227, 658-667.	4.1	410
13	Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. Journal of the National Cancer Institute, 2004, 96, 1702-1713.	6.3	395
14	Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?. Journal of the National Cancer Institute, 2002, 94, 805-818.	6.3	381
15	Tumor-Released Microvesicles as Vehicles of Immunosuppression. Cancer Research, 2007, 67, 2912-2915.	0.9	377
16	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Journal of Clinical Oncology, 2002, 20, 4169-4180.	1.6	361
17	Immune Surveillance Properties of Human NK Cell-Derived Exosomes. Journal of Immunology, 2012, 189, 2833-2842.	0.8	358
18	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	7.0	315

#	Article	IF	Citations
19	New common variants affecting susceptibility to basal cell carcinoma. Nature Genetics, 2009, 41, 909-914.	21.4	303
20	LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites. Journal of Immunology, 2010, 184, 6545-6551.	0.8	278
21	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology, The, 2012, 13, 879-886.	10.7	273
22	Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9461-9465.	7.1	254
23	Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Annals of Oncology, 2007, 18, 226-232.	1.2	252
24	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunological Reviews, 2002, 188, 97-113.	6.0	246
25	Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Seminars in Cancer Biology, 2012, 22, 342-349.	9.6	246
26	Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells. Cancer Research, 2006, 66, 3629-3638.	0.9	242
27	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	5.1	237
28	Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 255-263.	4.2	230
29	Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clinical Cancer Research, 2003, 9, 3235-45.	7.0	197
30	Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunology, Immunotherapy, 2008, 57, 303-315.	4.2	193
31	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Journal of Clinical Investigation, 2018, 128, 5505-5516.	8.2	193
32	Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).. Journal of Experimental Medicine, 1996, 184, 647-657.	8.5	164
33	TNF-Related Apoptosis-Inducing Ligand (TRAIL)â€“Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. Clinical Cancer Research, 2016, 22, 3499-3512.	7.0	158
34	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death and Disease, 2010, 1, e87-e87.	6.3	155
35	beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.. Journal of Clinical Investigation, 1998, 101, 2720-2729.	8.2	151
36	IFNÎ±-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood, 2004, 103, 3837-3844.	1.4	146

#	Article	IF	Citations
37	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
38	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
39	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-Î± in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2006, 55, 958-968.	4.2	134
40	Quantitation of antigen-reactive T cells in peripheral blood by IFNÎ³-ELISPOT assay and chromium-release assay: a four-centre comparative trial. Journal of Immunological Methods, 2000, 244, 81-89.	1.4	131
41	Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ Lesions. Journal of Immunotherapy, 1996, 19, 192-205.	2.4	130
42	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	9.4	124
43	Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors. Journal of Immunotherapy, 1996, 19, 266-277.	2.4	121
44	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. OncoImmunology, 2013, 2, e22058.	4.6	121
45	Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells. Journal of Immunology, 2003, 171, 3467-3474.	0.8	116
46	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunology, Immunotherapy, 2004, 53, 227-233.	4.2	116
47	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	21.4	111
48	Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-Î± Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. Cancer Research, 2006, 66, 4943-4951.	0.9	108
49	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	7.0	108
50	T-cell recognition of melanoma-associated antigens. Journal of Cellular Physiology, 2000, 182, 323-331.	4.1	106
51	Role of Cross-Talk between IFN-Î±-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens. Journal of Immunology, 2004, 172, 5363-5370.	0.8	103
52	Tumor necrosis factor-Î± induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood, 2001, 98, 1108-1115.	1.4	102
53	Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells. Journal of Experimental Medicine, 1999, 190, 205-216.	8.5	98
54	Proton dynamics in cancer. Journal of Translational Medicine, 2010, 8, 57.	4.4	97

#	Article	IF	Citations
55	Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5674-5678.	7.1	95
56	Effect Of Human Natural Killer and Î³Î´ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.9	90
57	Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin. Laboratory Investigation, 2003, 83, 1555-1567.	3.7	89
58	Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032. Neoplasia, 2011, 13, 1132-IN17.	5.3	89
59	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget, 2016, 7, 4428-4441.	1.8	84
60	Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1996, 7, 1955-1963.	2.7	83
61	Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein-barr virus-transformed B cells. International Journal of Cancer, 1994, 58, 69-79.	5.1	78
62	Cytokines in cancer therapy. Immunology Letters, 2000, 74, 41-44.	2.5	78
63	The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Research, 2003, 63, 4507-15.	0.9	78
64	Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. Journal of Investigative Dermatology, 2010, 130, 1877-1886.	0.7	77
65	Detection of mutated BRAFV600E variant in circulating DNA of stage IIIâ€“IV melanoma patients. International Journal of Cancer, 2007, 120, 2439-2444.	5.1	76
66	Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. Journal of Investigative Dermatology, 2014, 134, 1893-1902.	0.7	74
67	DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. International Journal of Cancer, 2005, 115, 224-230.	5.1	72
68	Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. Journal of Leukocyte Biology, 2006, 79, 123-132.	3.3	72
69	Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clinical Cancer Research, 2011, 17, 841-848.	7.0	70
70	In vitro antiâ€tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. International Journal of Cancer, 1993, 54, 8-15.	5.1	68
71	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 1994, 39, 193-197.	4.2	64
72	CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma. Cancer Research, 2008, 68, 715-723.	0.9	64

#	Article	IF	Citations
73	Factors, including transforming growth factor Î², released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunology, Immunotherapy, 1993, 36, 409-416.	4.2	63
74	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. Expert Opinion on Biological Therapy, 2005, 5, 463-476.	3.1	63
75	Heat Shock Proteins and Their Use as Anticancer Vaccines. Clinical Cancer Research, 2004, 10, 8142-8146.	7.0	62
76	Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells. Human Gene Therapy, 1999, 10, 2907-2916.	2.7	61
77	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class Iâ€“Modified Peptides. Clinical Cancer Research, 2012, 18, 6485-6496.	7.0	61
78	Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunology, Immunotherapy, 1993, 36, 315-322.	4.2	57
79	HLA Associations in the Antitumor Response Against Malignant Melanoma. Journal of Immunotherapy, 1995, 18, 242-252.	2.4	57
80	Melanoma immunology: past, present and future. Current Opinion in Oncology, 2007, 19, 121-127.	2.4	57
81	Multipeptide vaccination in cancer patients. Expert Opinion on Biological Therapy, 2009, 9, 1043-1055.	3.1	57
82	Modulation of multidrug resistance by verapamil ormdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers inmdr-resistant human carcinoma (LoVo) line. International Journal of Cancer, 1990, 46, 727-732.	5.1	55
83	Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Research, 2003, 63, 6948-55.	0.9	55
84	Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. Journal of Investigative Dermatology, 2009, 129, 1759-1768.	0.7	54
85	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open, 2016, 1, e000068.	4.5	54
86	pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. OncoImmunology, 2018, 7, e1445452.	4.6	54
87	Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase Îº as a Novel, Class II HLA-Restricted Melanoma Antigen. Journal of Immunology, 2003, 170, 6363-6370.	0.8	53
88	The high lysability by lak cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. International Journal of Cancer, 1991, 47, 746-754.	5.1	52
89	Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity. Cancer Research, 2006, 66, 4450-4460.	0.9	52
90	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51

#	Article	IF	Citations
91	Immunotherapy of melanoma. Seminars in Cancer Biology, 2003, 13, 391-400.	9.6	48
92	Adoptive transfer of an anti-MART-12735-specific CD8+ Tâ€„cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. European Journal of Immunology, 2003, 33, 556-566.	2.9	48
93	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 959-966.	0.8	48
94	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. Cancer Research, 2005, 65, 3942-3949.	0.9	47
95	Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. European Journal of Cancer, 1993, 29, 1266-1269.	2.8	45
96	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	4.4	45
97	Differences in Frequency Distribution of HLA-A2 Subtypes Between North American and Italian White Melanoma Patients: Relevance for Epitope Specific Vaccination Protocols. Journal of Immunotherapy, 1996, 19, 357-363.	2.4	43
98	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. Scientific Reports, 2018, 8, 8703.	3.3	43
99	Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunology, Immunotherapy, 1992, 34, 241-251.	4.2	42
100	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 407-420.	2.8	39
101	The Detection and Biological Activity of Human Antibodies to IL-2 in Normal Donors. Scandinavian Journal of Immunology, 1993, 38, 472-476.	2.7	35
102	More insights into the immunosuppressive potential of tumor exosomes. Journal of Translational Medicine, 2008, 6, 63.	4.4	33
103	Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy. Clinical Cancer Research, 2007, 13, 5675-5679.	7.0	32
104	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treatment Reviews, 2018, 65, 78-86.	7.7	32
105	Vaccination of patients with solid tumours. Annals of Oncology, 2003, 14, 817-824.	1.2	31
106	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunology, Immunotherapy, 2013, 62, 897-908.	4.2	31
107	Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Research, 2003, 63, 1560-7.	0.9	30
108	Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2. Tumori, 1990, 76, 566-571.	1.1	29

#	Article	IF	Citations
109	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget, 2014, 5, 4516-4528.	1.8	29
110	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. Journal of Investigative Dermatology, 2017, 137, 484-493.	0.7	29
111	Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8+ T Cells in One Vitiligo Patient. Journal of Investigative Dermatology, 2003, 121, 308-314.	0.7	28
112	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. Cancer Research, 2014, 74, 130-140.	0.9	27
113	Reconstitution of Human Telomerase Reverse Transcriptase Expression Rescues Colorectal Carcinoma Cells from In vitro Senescence: Evidence against Immortality as a Constitutive Trait of Tumor Cells. Cancer Research, 2005, 65, 2321-2329.	0.9	26
114	NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients. Clinical Cancer Research, 2007, 13, 7459-7468.	7.0	26
115	Rapid Generation of Full Clinical-Grade Human Antiadenovirus Cytotoxic T Cells for Adoptive Immunotherapy. Journal of Immunotherapy, 2010, 33, 414-424.	2.4	25
116	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. Journal of Clinical Medicine, 2020, 9, 930.	2.4	25
117	Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. British Journal of Haematology, 1991, 78, 197-205.	2.5	24
118	Murine granulocytes control human tumor growth in SCID mice. International Journal of Cancer, 2000, 87, 569-573.	5.1	24
119	Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses. Journal of Immunology, 2008, 181, 6525-6535.	0.8	24
120	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. Nature Communications, 2020, 11, 4274.	12.8	24
121	Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. European Journal of Cancer, 2005, 41, 1213-1222.	2.8	23
122	T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. Journal of Translational Medicine, 2005, 3, 3.	4.4	23
123	Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Review of Molecular Diagnostics, 2014, 14, 643-646.	3.1	23
124	Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity. Critical Reviews in Immunology, 1998, 18, 55-63.	0.5	23
125	Vaccination: role in metastatic melanoma. Expert Review of Anticancer Therapy, 2006, 6, 1305-1318.	2.4	22
126	Vaccination therapy in prostate cancer. Cancer Immunology, Immunotherapy, 2007, 56, 429-445.	4.2	21

#	Article	IF	Citations
127	Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. Cancer Immunology, Immunotherapy, 2009, 58, 1159-1167.	4.2	21
128	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. British Journal of Cancer, 2014, 111, 1350-1362.	6.4	21
129	Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Stem Cells, 2016, 34, 2449-2460.	3.2	21
130	Extracellular vesicles in anti-tumor immunity. Seminars in Cancer Biology, 2022, 86, 64-79.	9.6	21
131	Class I HLA Folding and Antigen Presentation in Î²2-Microglobulin-Defective Daudi Cells. Journal of Immunology, 2009, 182, 3609-3617.	0.8	20
132	Clinical and immunologic responses in melanoma patients vaccinated with MAGEâ€A3â€genetically modified lymphocytes. International Journal of Cancer, 2013, 132, 2557-2566.	5.1	20
133	Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines, 2016, 4, 38.	4.4	20
134	Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunology, Immunotherapy, 2007, 56, 1979-1991.	4.2	19
135	Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. Journal of Immunology Research, 2018, 2018, 1-13.	2.2	19
136	Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance. International Journal of Cancer, 1989, 43, 880-885.	5.1	18
137	Immunogenicity of the ALLAVGATK (gp10017â€‰â€“â€‰25) peptide in HLA-A3.1 melanoma patients. European Journal of Immunology, 1998, 28, 1143-1154.	2.9	18
138	A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. BMC Medical Genetics, 2014, 15, 59.	2.1	18
139	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Cell Communication and Signaling, 2020, 18, 156.	6.5	18
140	T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immunity, 2002, 2, 6.	3.2	18
141	HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy. Journal of Immunotherapy, 2010, 33, 402-413.	2.4	17
142	Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunology, Immunotherapy, 2015, 64, 83-89.	4.2	17
143	A novel computational method for automatic segmentation, quantification and comparative analysis of immunohistochemically labeled tissue sections. BMC Bioinformatics, 2018, 19, 357.	2.6	17
144	Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunology, Immunotherapy, 2001, 50, 199-211.	4.2	16

#	Article	IF	Citations
145	Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. OncoImmunology, 2014, 3, e967146.	4.6	16
146	Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer, 2015, 15, 58.	2.6	14
147	Heat shock proteins gp96 as immunogens in cancer patients. International Journal of Hyperthermia, 2006, 22, 223-227.	2.5	13
148	Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation. Journal of Immunology, 2008, 180, 3782-3788.	0.8	13
149	Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis, 2012, 33, 781-790.	2.8	13
150	Melanoma Cells Homing to the Brain: AnIn VitroModel. BioMed Research International, 2015, 2015, 1-11.	1.9	13
151	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
152	Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). Annals of Oncology, 2018, 29, viii312.	1.2	12
153	microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1214.	4.8	12
154	Y⁹⁰-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut, 2023, 72, 406-407.	12.1	12
155	Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx). International Journal of Cancer, 1988, 42, 544-548.	5.1	11
156	Biologic agents as modifiers of chemotherapeutic effects. Current Opinion in Oncology, 1991, 3, 1078-1086.	2.4	11
157	MIAQuant, a novel system for automatic segmentation, measurement, and localization comparison of different biomarkers from serialized histological slices. European Journal of Histochemistry, 2017, 61, 2838.	1.5	11
158	Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients. BMC Cancer, 2018, 18, 983.	2.6	11
159	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
160	Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. Melanoma Research, 1992, 2, 263-272.	1.2	10
161	Induction of Both CD8+ and CD4+ T-Cellâ€“Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1. Clinical Cancer Research, 2008, 14, 7292-7303.	7.0	10
162	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Critical Reviews in Oncology/Hematology, 2019, 139, 149-157.	4.4	10

#	Article	IF	Citations
163	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541984640.	2.0	10
164	Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK). Cancer and Metastasis Reviews, 1988, 7, 335-345.	5.9	9
165	Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. Annals of Oncology, 1992, 3, 155-162.	1.2	9
166	T-cell recognition of melanoma antigens and its therapeutic applications. International Journal of Clinical and Laboratory Research, 1997, 27, 103-110.	1.0	9
167	Antitumor activity of delimotecan against human metastatic melanoma: Pharmacokinetics and molecular determinants. International Journal of Cancer, 2009, 125, 2456-2464.	5.1	8
168	Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Targeted Oncology, 2015, 10, 277-286.	3.6	8
169	microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes, 2016, 7, 124.	2.4	8
170	Mechanisms of tumor immunotherapy, with a focus on thoracic cancers. Journal of Thoracic Disease, 2018, 10, 4619-4631.	1.4	8
171	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. Cancer Prevention Research, 2021, 14, 963-972.	1.5	8
172	Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. Melanoma Research, 2002, 12, 491-498.	1.2	7
173	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunology, Immunotherapy, 1994, 39, 193-197.	4.2	7
174	Spheres of Influence in Cancer Stem Cell Biology. Journal of Investigative Dermatology, 2011, 131, 546-547.	0.7	6
175	Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. Journal of Translational Medicine, 2013, 11, 237.	4.4	6
176	Immune response markers in sentinel nodes may predict melanoma progression. OncoImmunology, 2014, 3, e28498.	4.6	6
177	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. Journal of Investigative Dermatology, 2022, 142, 3030-3040.e5.	0.7	6
178	Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells. Journal of Immunotherapy, 2000, 23, 405-411.	2.4	5
179	The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer. Cancer Research, 2019, 79, 3169-3171.	0.9	5
180	A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: The BONSAI trial.. Journal of Clinical Oncology, 2019, 37, 578-578.	1.6	5

#	Article	IF	Citations
181	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	3.7	4
182	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 2020, 12, 617.	3.7	4
183	Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients. Clinical Cancer Research, 2005, 11, 7587-7588.	7.0	3
184	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. Journal of Investigative Dermatology, 2014, 134, 1389-1396.	0.7	3
185	Monitoring the Frequency and Function of Regulatory T Cells and Summary of the Approaches Currently Used to Inhibit Regulatory T Cells in Cancer Patients. Methods in Molecular Biology, 2014, 1139, 201-221.	0.9	3
186	ITOC2 â€“ 038. Role of exosomes in immune suppression. European Journal of Cancer, 2015, 51, S13.	2.8	3
187	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine, 2021, 11, e434.	4.0	3
188	A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer. Tumori, 1988, 74, 523-530.	1.1	2
189	Microarray Analysis for Monitoring the Response to Interferon. Journal of Immunotherapy, 2005, 28, 619-620.	2.4	2
190	Exploiting liver immunity for the prevention of hepatic metastases. Journal of Hepatology, 2010, 53, 596-598.	3.7	2
191	Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients. Genes, 2021, 12, 1440.	2.4	2
192	T cell response to tumor antigens and its therapeutic use in cancer patients. Advances in Experimental Medicine and Biology, 2001, 495, 403-410.	1.6	2
193	Abstract B022: Metabolic and immunologic effects of the fasting mimicking diet in cancer patients. , 2018, , .		2
194	Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC). Journal of Clinical Oncology, 2008, 26, 5121-5121.	1.6	2
195	Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG).. Journal of Clinical Oncology, 2010, 28, 4615-4615.	1.6	2
196	Safety and metabolic effects of cyclic fasting mimicking diet (FMD) in cancer patients.. Journal of Clinical Oncology, 2018, 36, e14549-e14549.	1.6	2
197	A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.. Journal of Clinical Oncology, 2019, 37, TPS685-TPS685.	1.6	2
198	Correction: CCN3 Increases Integrin Expression and Adhesion. Cancer Research, 2008, 68, 2051-2051.	0.9	1

#	Article	IF	Citations
199	Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients. Annals of Oncology, 2017, 28, vi17.	1.2	1
200	Tumor-Derived Exosomes as Dendritic Cell Modulators. , 2009, , 119-128.		1
201	Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab.. Journal of Clinical Oncology, 2020, 38, 719-719.	1.6	1
202	Evaluation of Myeloid Suppressive Cells in Peripheral Blood of Melanoma Patients and Their Modulation by A Heat-shock Protein (HSP)-96 and GM-CSF-based Vaccine. Journal of Immunotherapy, 2005, 28, 659.	2.4	0
203	Vaccination with Survivin and PSMA-derived Peptides: A Pilot Study in Prostate Cancer Patients Failing Radiotherapy or Surgery. International Journal of Radiation Oncology Biology Physics, 2009, 75, S14.	0.8	0
204	Response to Griewank and Bastian. Journal of Investigative Dermatology, 2010, 130, 2331-2332.	0.7	0
205	Don't run before you can walk. Nature Reviews Urology, 2012, 9, 602-602.	3.8	0
206	Tumor Exosomes and Their Impact on Immunity and Cancer Progression. , 2013, , 517-535.		0
207	Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies. , 2021, , 99-128.		0
208	Altered peptide ligands of tumor T-cell epitopes. , 2003, , 97-110.		0
209	CCN3 Promotes Melanoma Progression by Regulating Integrin Expression, Adhesion and Apoptosis Induced by Cytotoxic Drugs. , 2010, , 205-211.		0
210	Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response (LTR) to vemurafenib (Vb).. Journal of Clinical Oncology, 2017, 35, e21001-e21001.	1.6	0
211	Abstract 4981: Circulating mir-320 promotes immunosuppressive macrophages M2 phenotype associated with lung cancer progression. , 2018, , .		0
212	Abstract 3517: Targeting pH regulators to modulate human hepatocellular carcinoma microenvironment. , 2018, , .		0
213	The ACC melanoma pilot project: â€œReal-worldâ€•evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	1.6	0